$-0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS)
February 7, 2018 – By Winifred Garcia
Analysts expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to report $-0.25 EPS on March, 8.They anticipate $0.19 EPS change or 43.18 % from last quarter’s $-0.44 EPS. After having $-0.43 EPS previously, Sunesis Pharmaceuticals, Inc.’s analysts see -41.86 % EPS growth. The stock increased 1.19% or $0.07 during the last trading session, reaching $5.97. About 198,671 shares traded or 17.64% up from the average. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since February 7, 2017 and is uptrending. It has underperformed by 8.37% the S&P500.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Coverage
Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Sunesis Pharmaceuticals had 11 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 11 by Wells Fargo. As per Tuesday, July 18, the company rating was maintained by Cantor Fitzgerald. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, December 5. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has “Buy” rating given on Thursday, December 14 by Oppenheimer. On Friday, July 24 the stock rating was downgraded by TH Capital to “Sell”. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has “Buy” rating given on Monday, November 20 by Oppenheimer. Cantor Fitzgerald downgraded Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) on Friday, July 24 to “Hold” rating. The company was maintained on Thursday, July 27 by Cantor Fitzgerald. Wells Fargo upgraded the shares of SNSS in report on Friday, July 29 to “Outperform” rating. As per Friday, July 24, the company rating was downgraded by Cowen & Co.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $204.46 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.
More notable recent Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) news were published by: Seekingalpha.com which released: “Sunesis Pharmaceuticals: Overhang Cleared For This Oncology Turnaround Story” on October 26, 2017, also Globenewswire.com with their article: “Sunesis Pharmaceuticals Added to Russell Microcap® Index” published on June 26, 2017, Seekingalpha.com published: “Sunesis Pharmaceuticals: SNS-062 Could Be The Company’s Salvation” on August 29, 2017. More interesting news about Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) were released by: Streetinsider.com and their article: “Sunesis Pharmaceuticals (SNSS) Prices of $20 Million Offering of Common Stock …” published on October 25, 2017 as well as Streetinsider.com‘s news article titled: “UPDATE: Oppenheimer Starts Sunesis Pharmaceuticals Inc. (SNSS) at Outperform” with publication date: November 21, 2017.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.